{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:18:49Z","timestamp":1789175929372,"version":"build-2803163510"},"reference-count":160,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.lungcan.2023.02.018","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T17:25:53Z","timestamp":1677691553000},"page":"254-268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["MET alterations in advanced non-small cell lung cancer"],"prefix":"10.1016","volume":"178","author":[{"given":"Mandy","family":"Sakamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4389-1010","authenticated-orcid":false,"given":"Tejas","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.lungcan.2023.02.018_b0005","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The Effect of Advances in Lung-Cancer Treatment on Population Mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.lungcan.2023.02.018_b0010","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.2014.60.7317","article-title":"Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non\u2013Small-Cell Lung Cancer","volume":"33","author":"Scagliotti","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2023.02.018_b0015","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.2016.69.2160","article-title":"Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non\u2013Small-Cell Lung Cancer: METLung","volume":"35","author":"Spigel","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2023.02.018_b0020","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/annonc\/mdv288","article-title":"A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB\/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal","volume":"26","author":"Yoshioka","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2023.02.018_b0025","doi-asserted-by":"crossref","unstructured":"Mok TSK, Park K, Geater SL, et al. A Randomized Phase (PH) 2 Study with Exploratory Biomarker Analysis of Ficlatuzumab (F) A Humanized Hepatocyte Growth Factor (HGF) Inhibitory MAB in Combination with Gefitinib (G) Versus G in Asian Patients (PTS) with Lung Adenocarcinoma (LA). Ann Oncol. 2012;23:ix391. doi:10.1016\/S0923-7534(20)33782-0.","DOI":"10.1016\/S0923-7534(20)33782-0"},{"issue":"5","key":"10.1016\/j.lungcan.2023.02.018_b0030","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cllc.2012.01.003","article-title":"Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non\u2013Small-Cell Lung Cancer","volume":"13","author":"Scagliotti","year":"2012","journal-title":"Clin. Lung Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2023.02.018_b0035","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/jclinpath-2015-203050","article-title":"Gene of the month: MET","volume":"68","author":"Skead","year":"2015","journal-title":"J. Clin. Pathol."},{"issue":"6","key":"10.1016\/j.lungcan.2023.02.018_b0040","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nrd2530","article-title":"Drug development of MET inhibitors: targeting oncogene addiction and expedience","volume":"7","author":"Comoglio","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lungcan.2023.02.018_b0045","article-title":"An overview of the c-MET signaling pathway. Ther Adv","volume":"3(1_suppl):S7\u2013S19","author":"Organ","year":"2011","journal-title":"Med. Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2023.02.018_b0050","doi-asserted-by":"crossref","first-page":"12039","DOI":"10.1073\/pnas.2034936100","article-title":"Functional map and domain structure of MET, the product of the c- met protooncogene and receptor for hepatocyte growth factor\/scatter factor","volume":"100","author":"Gherardi","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.lungcan.2023.02.018_b0055","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2147\/OTT.S44941","article-title":"Emerging molecular targets in oncology: clinical potential of MET\/hepatocyte growth-factor inhibitors","author":"Smyth","year":"2014","journal-title":"Onco Targets Ther."},{"issue":"1","key":"10.1016\/j.lungcan.2023.02.018_b0060","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/JTO.0b013e3181913e0e","article-title":"Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers","volume":"4","author":"Onozato","year":"2009","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2023.02.018_b0065","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","article-title":"Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors","volume":"5","author":"Frampton","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2023.02.018_b0070","article-title":"Characterization of 1,387 NSCLCs with MET exon 14 (METex14) skipping alterations (SA) and potential acquired resistance (AR) mechanisms","volume":"38(15_suppl):9511\u20139511","author":"Awad","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2023.02.018_b0075","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw262","article-title":"Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers. JNCI","volume":"109","author":"Cortot","year":"2017","journal-title":"J. Natl Cancer Inst."},{"issue":"1","key":"10.1016\/j.lungcan.2023.02.018_b0080","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jtho.2016.10.014","article-title":"Targeting MET in Lung Cancer: Will Expectations Finally Be MET?","volume":"12","author":"Drilon","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"7511","key":"10.1016\/j.lungcan.2023.02.018_b0085","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"Comprehensive molecular profiling of lung adenocarcinoma","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2023.02.018_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00356","article-title":"Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non\u2013Small-Cell Lung Cancer Using a Decision Analytic Model","volume":"3","author":"Pennell","year":"2019","journal-title":"JCO Precis. Oncol."},{"issue":"16","key":"10.1016\/j.lungcan.2023.02.018_b0095","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1158\/1078-0432.CCR-14-2683","article-title":"Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches","volume":"21","author":"Drilon","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.lungcan.2023.02.018_b0100","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.jtho.2017.07.026","article-title":"MET Exon 14 Alterations and New Resistance Mutations to Tyrosine Kinase Inhibitors: Risk of Inadequate Detection with Current Amplicon-Based NGS Panels","volume":"12","author":"Poirot","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2023.02.018_b0105","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jmoldx.2017.01.011","article-title":"Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels","volume":"19","author":"Jennings","year":"2017","journal-title":"J Mol Diagnostics."},{"issue":"12","key":"10.1016\/j.lungcan.2023.02.018_b0110","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/j.jtho.2018.08.2023","article-title":"Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients","volume":"13","author":"Descarpentries","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2023.02.018_b0115","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nmeth.1419","article-title":"Target-enrichment strategies for next-generation sequencing","volume":"7","author":"Mamanova","year":"2010","journal-title":"Nat. Methods"},{"issue":"7","key":"10.1016\/j.lungcan.2023.02.018_b0120","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","article-title":"MET Exon 14 Mutations in Non\u2013Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression","volume":"34","author":"Awad","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2023.02.018_b0125","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00428-018-2411-4","article-title":"Validation of the OncomineTM focus panel for next-generation sequencing of clinical tumour samples","volume":"473","author":"Williams","year":"2018","journal-title":"Virchows Arch."},{"issue":"12","key":"10.1016\/j.lungcan.2023.02.018_b0130","doi-asserted-by":"crossref","first-page":"e1294","DOI":"10.1634\/theoncologist.2019-0236","article-title":"An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies","volume":"24","author":"Cao","year":"2019","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.lungcan.2023.02.018_b0135","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jtho.2018.12.020","article-title":"DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer","volume":"14","author":"Davies","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.02.018_b0140","doi-asserted-by":"crossref","unstructured":"von Ahlfen S, Missel A, Bendrat K, Schlumpberger M. Determinants of RNA Quality from FFPE Samples. Fraser P, ed. PLoS One. 2007;2(12):e1261. doi:10.1371\/journal.pone.0001261.","DOI":"10.1371\/journal.pone.0001261"},{"issue":"1","key":"10.1016\/j.lungcan.2023.02.018_b0145","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1472-6750-7-57","article-title":"Characterization of the effect of sample quality on high density oligonucleotide microarray data using progressively degraded rat liver RNA","volume":"7","author":"Thompson","year":"2007","journal-title":"BMC Biotech."},{"issue":"4","key":"10.1016\/j.lungcan.2023.02.018_b0150","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/labinvest.3700529","article-title":"RNA expression analysis of formalin-fixed paraffin-embedded tumors","volume":"87","author":"Penland","year":"2007","journal-title":"Lab Investig."},{"issue":"15","key":"10.1016\/j.lungcan.2023.02.018_b0155","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1158\/1078-0432.CCR-19-0225","article-title":"High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden","volume":"25","author":"Benayed","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2023.02.018_b0160","article-title":"Efficacy of DNA versus RNA NGS-based Methods in MET Exon 14 skipping mutation detection","volume":"38(15_suppl):9036\u20139036","author":"Jurkiewicz","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2023.02.018_b0165","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41416-022-01777-8","article-title":"Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?","volume":"127","author":"Bonanno","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2023.02.018_b0170","article-title":"Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance. npj Precis","volume":"4(1):15","author":"Schwartzberg","year":"2020","journal-title":"Oncol."},{"key":"10.1016\/j.lungcan.2023.02.018_b0175","article-title":"Concordance of next-generation sequencing between tissue and liquid biopsies in non-small cell lung cancer","volume":"38(15_suppl):e21547\u2013e21547","author":"Basher","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.lungcan.2023.02.018_b0180","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1158\/1078-0432.CCR-16-1231","article-title":"Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA","volume":"22","author":"Thompson","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.lungcan.2023.02.018_b0185","doi-asserted-by":"crossref","DOI":"10.3390\/cells9020522","article-title":"Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients","volume":"9","author":"Mondelo-Mac\u00eda","year":"2020","journal-title":"Cells."},{"issue":"11","key":"10.1016\/j.lungcan.2023.02.018_b0190","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jtho.2019.08.003","article-title":"Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer","volume":"14","author":"Horn","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2023.02.018_b0195","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology","volume":"20","author":"Heitzer","year":"2019","journal-title":"Nat. Rev. Genet."},{"issue":"7","key":"10.1016\/j.lungcan.2023.02.018_b0200","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2174\/1568009618666180308125110","article-title":"Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR- Mutation Testing in NSCLC Patients: a Pooled Analysis","volume":"18","author":"Passiglia","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.lungcan.2023.02.018_b0205","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1200\/PO.21.00122","article-title":"Characterization of Non\u2013Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns","volume":"5","author":"Lee","year":"2021","journal-title":"JCO Precis. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2023.02.018_b0210","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in Non\u2013Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2023.02.018_b0215","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-2061","article-title":"MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis","volume":"22","author":"Tong","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2023.02.018_b0220","article-title":"Detection of frequent MET Exon 14 skipping events in pulmonary sarcomatoid carcinoma and response to targeted inhibition","volume":"33(15_suppl):8020\u20138020","author":"Liu","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.02.018_b0225","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cllc.2018.08.020","article-title":"Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations","volume":"20","author":"Lam","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2023.02.018_b0230","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2018.07.006","article-title":"Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer \u2013 A systematic review and meta-analysis","volume":"123","author":"Vuong","year":"2018","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.lungcan.2023.02.018_b0235","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/2159-8290.CD-14-1467","article-title":"Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping","volume":"5","author":"Paik","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2023.02.018_b0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00011","article-title":"Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR -Mutated Lung Cancer","volume":"3","author":"Suzawa","year":"2019","journal-title":"JCO Precis. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2023.02.018_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtocrr.2020.100082","article-title":"Acquired Exon 14 MET Mutation Associated With Resistance to Alectinib in a Patient With ALK\u2013Rearranged NSCLC","volume":"1","author":"Daniel","year":"2020","journal-title":"JTO Clin Res Reports."},{"issue":"12","key":"10.1016\/j.lungcan.2023.02.018_b0250","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/gcc.20604","article-title":"Expression and mutational analysis of MET in human solid cancers","volume":"47","author":"Ma","year":"2008","journal-title":"Genes Chromosom. Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2023.02.018_b0255","first-page":"197","article-title":"High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients","volume":"27","author":"Park","year":"2012","journal-title":"Histol. Histopathol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.02.018_b0260","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/hupa.2001.21133","article-title":"Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non\u2013small-cell lung cancer","volume":"32","author":"Tsao","year":"2001","journal-title":"Hum. Pathol."},{"issue":"2","key":"10.1016\/j.lungcan.2023.02.018_b0265","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/JTO.0b013e318241655f","article-title":"c-MET\/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung Carcinomas","volume":"7","author":"Tsuta","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2023.02.018_b0270","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jtho.2019.06.009","article-title":"MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium","volume":"14","author":"Guo","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2023.02.018_b0275","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrclinonc.2012.71","article-title":"MET: a promising anticancer therapeutic target","volume":"9","author":"Peters","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.02.018_b0280","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.lungcan.2021.12.016","article-title":"Targeting un-MET needs in advanced non-small cell lung cancer","volume":"164","author":"Coleman","year":"2022","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2023.02.018_b0285","first-page":"83","article-title":"Prognostic and predictive value of MET deregulation in non-small cell lung cancer","volume":"3","author":"Finocchiaro","year":"2015","journal-title":"Ann Transl Med."},{"issue":"18","key":"10.1016\/j.lungcan.2023.02.018_b0290","doi-asserted-by":"crossref","first-page":"16215","DOI":"10.18632\/oncotarget.3976","article-title":"MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)","volume":"6","author":"Casadevall","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2023.02.018_b0295","doi-asserted-by":"crossref","unstructured":"Lo AW l., Sabatier L, Fouladi B, Pottier G, Ricoul M, Mumane JP. DNA Amplification by Breakage\/Fusion\/Bridge Cycles Initiated by Spontaneous Telomere Loss in a Human Cancer Cell Line. Neoplasia. 2002;4(6):531-538. doi:10.1038\/sj.neo.7900267.","DOI":"10.1038\/sj.neo.7900267"},{"issue":"1","key":"10.1016\/j.lungcan.2023.02.018_b0300","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1535-6108(02)00017-X","article-title":"A role for common fragile site induction in amplification of human oncogenes","volume":"1","author":"Hellman","year":"2002","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.lungcan.2023.02.018_b0305","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/ng1215","article-title":"Chromosome aberrations in solid tumors","volume":"34","author":"Albertson","year":"2003","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.lungcan.2023.02.018_b0310","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/JTO.0b013e3181ce3d1d","article-title":"High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer","volume":"5","author":"Go","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2023.02.018_b0315","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3390\/cancers6031540","article-title":"Targeting MET Amplification as a New Oncogenic Driver","volume":"6","author":"Kawakami","year":"2014","journal-title":"Cancers (Basel)."},{"issue":"10","key":"10.1016\/j.lungcan.2023.02.018_b0320","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1200\/JCO.2008.19.1635","article-title":"Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non\u2013Small-Cell Lung Cancer Patients","volume":"27","author":"Cappuzzo","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2023.02.018_b0325","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jtho.2016.04.033","article-title":"Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis","volume":"11","author":"Noonan","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2023.02.018_b0330","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat Cancer."},{"key":"10.1016\/j.lungcan.2023.02.018_b0335","article-title":"Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (MET amp)","volume":"39(15_suppl):9021\u20139021","author":"Le","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2023.02.018_b0340","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jtho.2021.02.010","article-title":"Crizotinib in Patients With MET-Amplified NSCLC","volume":"16","author":"Camidge","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"24","key":"10.1016\/j.lungcan.2023.02.018_b0345","first-page":"7312","article-title":"Crizotinib in MET -Deregulated or ROS1 -Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter","volume":"25","author":"Landi","year":"2019","journal-title":"Two-Arms Trial. Clin Cancer Res."},{"issue":"10","key":"10.1016\/j.lungcan.2023.02.018_b0350","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET Exon 14\u2013Mutated or MET -Amplified Non\u2013Small-Cell Lung Cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.lungcan.2023.02.018_b0355","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.lungcan.2023.02.018_b0360","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1093\/annonc\/mdv319","article-title":"EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients","volume":"26","author":"Planchard","year":"2015","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2023.02.018_b0365","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1158\/1078-0432.CCR-19-3906","article-title":"MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer","volume":"26","author":"Dagogo-Jack","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"25","key":"10.1016\/j.lungcan.2023.02.018_b0370","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.19.03123","article-title":"Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review","volume":"38","author":"Piper-Vallillo","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2023.02.018_b0375","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1097-2765(01)00378-1","article-title":"Mutation of the c-Cbl TKB Domain Binding Site on the Met Receptor Tyrosine Kinase Converts It into a Transforming Protein","volume":"8","author":"Peschard","year":"2001","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.lungcan.2023.02.018_b0380","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1038\/ncomms5846","article-title":"The landscape of kinase fusions in cancer","volume":"5","author":"Stransky","year":"2014","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.lungcan.2023.02.018_b0385","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1158\/1078-0432.CCR-17-3001","article-title":"Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients","volume":"24","author":"Plenker","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2023.02.018_b0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00117","article-title":"Dramatic Response to Crizotinib in a Patient With Lung Cancer Positive for an HLA-DRB1-MET Gene Fusion","volume":"1","author":"Davies","year":"2017","journal-title":"JCO Precis. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2023.02.018_b0395","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1093\/annonc\/mdy455","article-title":"Identification of a novel crizotinib-sensitive MET\u2013ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing","volume":"29","author":"Zhu","year":"2018","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2023.02.018_b0400","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.jtho.2019.07.022","article-title":"Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population","volume":"14","author":"Pan","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2023.02.018_b0405","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1158\/1078-0432.CCR-19-3608","article-title":"Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14\u2013Mutant NSCLC","volume":"26","author":"Recondo","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2023.02.018_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102022","article-title":"The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping","volume":"87","author":"Salgia","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.lungcan.2023.02.018_b0415","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.lungcan.2016.11.011","article-title":"The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable","volume":"103","author":"Reungwetwattana","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2023.02.018_b0420","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.lungcan.2019.05.011","article-title":"Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis","volume":"133","author":"Awad","year":"2019","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2023.02.018_b0425","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41591-019-0716-8","article-title":"Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration","volume":"26","author":"Drilon","year":"2020","journal-title":"Nat. Med."},{"issue":"25","key":"10.1016\/j.lungcan.2023.02.018_b0430","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2023.02.018_b0435","unstructured":"Pfizer\u2019s XALKORI\u00ae (crizotinib) Receives FDA Breakthrough Therapy Designation in Two New Indications | Pfizer. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_s_xalkori_crizotinib_receives_fda_breakthrough_therapy_designation_in_two_n."},{"issue":"7818","key":"10.1016\/j.lungcan.2023.02.018_b0440","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41586-020-2481-8","article-title":"The National Lung Matrix Trial of personalized therapy in lung cancer","volume":"583","author":"Middleton","year":"2020","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.lungcan.2023.02.018_b0445","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/annonc\/mdz407","article-title":"Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcS\u00e9 phase II trial","volume":"30","author":"Moro-Sibilot","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2023.02.018_b0450","unstructured":"FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-capmatinib-metastatic-non-small-cell-lung-cancer."},{"key":"10.1016\/j.lungcan.2023.02.018_b0455","article-title":"Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study","volume":"39(15_suppl):9020\u20139020","author":"Wolf","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.02.018_b0460","unstructured":"Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation (GeoMETry-III). ClinicalTrials.gov Identifier: NCT04427072. https:\/\/clinicaltrials.gov\/ct2."},{"key":"10.1016\/j.lungcan.2023.02.018_b0465","unstructured":"Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1\u2265 50%. ClinicalTrials.gov Identifier: NCT04139317. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04139317."},{"key":"10.1016\/j.lungcan.2023.02.018_b0470","unstructured":"Study of Capmatinib and Spartalizumab\/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations. ClinicalTrials.gov Identifier: NCT04323436. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04323436."},{"key":"10.1016\/j.lungcan.2023.02.018_b0475","unstructured":"FDA grants accelerated approval to tepotinib for metastatic non-small cell lung cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-tepotinib-metastatic-non-small-cell-lung-cancer."},{"key":"10.1016\/j.lungcan.2023.02.018_b0480","unstructured":"Thomas M, Garassino MC, Felip E, et al. Tepotinib in patients with MET exon 14 skipping NSCLC: primary analysis of the confirmatory VISION cohort C. Presented at: International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer."},{"issue":"14","key":"10.1016\/j.lungcan.2023.02.018_b0485","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s40265-021-01584-0","article-title":"Savolitinib: First Approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.lungcan.2023.02.018_b0490","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S2213-2600(21)00084-9","article-title":"Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study","volume":"9","author":"Lu","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lungcan.2023.02.018_b0495","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.annonc.2022.02.011","article-title":"2MO Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLC","volume":"33","author":"Lu","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2023.02.018_b0500","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221107112","article-title":"Cabozantinib for the treatment of solid tumors: a systematic review","volume":"14","author":"Maroto","year":"2022","journal-title":"Ther Adv Med Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2023.02.018_b0505","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2023.02.018_b0510","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejca.2017.09.011","article-title":"Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours","volume":"86","author":"Sch\u00f6ffski","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2023.02.018_b0515","first-page":"9","author":"Reckamp","year":"2019","journal-title":"Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2023.02.018_b0520","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/S1470-2045(16)30561-7","article-title":"Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial","volume":"17","author":"Neal","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2023.02.018_b0525","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.2147\/OTT.S231257","article-title":"MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF\/c-Met Axis","volume":"13","author":"Liang","year":"2020","journal-title":"Onco Targets Ther."},{"issue":"5","key":"10.1016\/j.lungcan.2023.02.018_b0530","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/CAD.0000000000000765","article-title":"Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib","volume":"30","author":"Wang","year":"2019","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1016\/j.lungcan.2023.02.018_b0535","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jtho.2016.09.127","article-title":"Intracranial Activity of Cabozantinib in MET Exon 14\u2013Positive NSCLC with Brain Metastases","volume":"12","author":"Klempner","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"16","key":"10.1016\/j.lungcan.2023.02.018_b0540","doi-asserted-by":"crossref","DOI":"10.21037\/atm-21-3861","article-title":"A rapid and durable response to cabozantinib in an osimertinib- resistant lung cancer patient with MET D1228N mutation: a case report","volume":"9","author":"Kuang","year":"2021","journal-title":"Ann Transl Med."},{"issue":"4","key":"10.1016\/j.lungcan.2023.02.018_b0545","doi-asserted-by":"crossref","first-page":"e24300","DOI":"10.1097\/MD.0000000000024300","article-title":"Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation","volume":"100","author":"Qin","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.lungcan.2023.02.018_b0550","unstructured":"Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer.ClinicalTrials.gov Identifier: NCT03468985. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03468985."},{"key":"10.1016\/j.lungcan.2023.02.018_b0555","unstructured":"Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity. ClinicalTrials.gov Identifier: NCT01639508. https:\/\/clinicaltrials.gov\/ct2\/show\/NC."},{"issue":"1","key":"10.1016\/j.lungcan.2023.02.018_b0560","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jtho.2019.10.003","article-title":"A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients","volume":"15","author":"Scagliotti","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.02.018_b0565","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s10020-018-0051-4","article-title":"Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics","volume":"24","author":"Runcie","year":"2018","journal-title":"Mol. Med."},{"key":"10.1016\/j.lungcan.2023.02.018_b0570","unstructured":"FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-amivantamab-vmjw-metastatic-non-small-cell-lung-cancer."},{"issue":"10","key":"10.1016\/j.lungcan.2023.02.018_b0575","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1535-7163.MCT-20-0071","article-title":"Amivantamab (JNJ-61186372), an Fc Enhanced EGFR\/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte\/Macrophage Trogocytosis","volume":"19","author":"Vijayaraghavan","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2023.02.018_b0580","unstructured":"Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (CHRYSALIS). ClinicalTrials.gov Identifier: NCT02609776. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02609776."},{"key":"10.1016\/j.lungcan.2023.02.018_b0585","article-title":"Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study","volume":"40(16_suppl):9008\u20139008","author":"Krebs","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.02.018_b0590","doi-asserted-by":"crossref","first-page":"S951","DOI":"10.1016\/j.annonc.2021.08.1797","article-title":"1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study","volume":"32","author":"Leighl","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2023.02.018_b0595","unstructured":"A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (Chrysalis-2). ClinicalTrials.gov Identifier: NCT04077463. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04077463."},{"key":"10.1016\/j.lungcan.2023.02.018_b0600","unstructured":"A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic NSCLC After Osimertinib Failure (MARIPOSA-2).ClinicalTrials.gov Identifier: NCT04988295. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04988295."},{"key":"10.1016\/j.lungcan.2023.02.018_b0605","unstructured":"A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA).ClinicalTrials.gov Identifier: NCT04487080. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04487080."},{"key":"10.1016\/j.lungcan.2023.02.018_b0610","unstructured":"REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer. ClinicalTrials.gov Identifier: NCT04077099. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04077099."},{"key":"10.1016\/j.lungcan.2023.02.018_b0615","doi-asserted-by":"crossref","first-page":"S1085","DOI":"10.1016\/j.annonc.2022.07.1296","article-title":"1173P Early safety, tolerability, and efficacy of REGN5093 in patients (pts) with MET-altered advanced non-small cell lung cancer (aNSCLC) from a first in human (FIH) study","volume":"33","author":"Cho","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2023.02.018_b0620","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.lungcan.2021.12.002","article-title":"Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer","volume":"163","author":"Desai","year":"2022","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2023.02.018_b0625","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.lungcan.2023.02.018_b0630","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.lungcan.2021.11.016","article-title":"Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach","volume":"163","author":"Marks","year":"2022","journal-title":"Lung Cancer"},{"issue":"16_suppl","key":"10.1016\/j.lungcan.2023.02.018_b0635","doi-asserted-by":"crossref","first-page":"9016","DOI":"10.1200\/JCO.2022.40.16_suppl.9016","article-title":"Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met\u2013overexpressing (OE) advanced non-small cell lung cancer (NSCLC)","volume":"40","author":"Camidge","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.02.018_b0640","unstructured":"Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer. ClinicalTrials.gov Identifier: NCT03539536.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03539536."},{"issue":"16_suppl","key":"10.1016\/j.lungcan.2023.02.018_b0645","doi-asserted-by":"crossref","first-page":"TPS8593","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8593","article-title":"A phase 1\/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC","volume":"40","author":"Drilon","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2023.02.018_b0650","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1158\/1535-7163.MCT-21-0009","article-title":"A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade","volume":"20","author":"DaSilva","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2023.02.018_b0655","unstructured":"Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer. ClinicalTrials.gov Identifier: NCT04982224.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04982224."},{"issue":"11","key":"10.1016\/j.lungcan.2023.02.018_b0660","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M\u2013Positive Lung Cancer and Acquired Resistance to Osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2023.02.018_b0665","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"31","key":"10.1016\/j.lungcan.2023.02.018_b0670","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.2018.77.7326","article-title":"Phase Ib\/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR -Mutated, MET Factor-Dysregulated Non\u2013Small-Cell Lung Cancer","volume":"36","author":"Wu","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2023.02.018_b0675","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10637-020-01010-4","article-title":"A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer","volume":"39","author":"Yang","year":"2021","journal-title":"Invest. New Drugs"},{"issue":"11","key":"10.1016\/j.lungcan.2023.02.018_b0680","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/S2213-2600(20)30154-5","article-title":"Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b\/2, multicentre, randomised trial","volume":"8","author":"Wu","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lungcan.2023.02.018_b0685","doi-asserted-by":"crossref","first-page":"S978","DOI":"10.1016\/j.annonc.2021.08.1844","article-title":"1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib","volume":"32","author":"Yu","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2023.02.018_b0690","doi-asserted-by":"crossref","unstructured":"Ahn MJ, de Marinis F, Bonanno L et al. Ahn MJ, de Marinis F, Bonanno L, et al. MET biomarker-based preliminary efficacy analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC post-osimertinib.Presented at: International Association for the Study of Lung Cancer. 2022 World Conference on Lung Cancer; August 6-9, 2022; Vienna, Austria.","DOI":"10.1016\/j.jtho.2022.07.823"},{"key":"10.1016\/j.lungcan.2023.02.018_b0695","doi-asserted-by":"crossref","first-page":"S1419","DOI":"10.1016\/j.annonc.2022.08.054","article-title":"LBA52 Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study","volume":"33","author":"Mazieres","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2023.02.018_b0700","doi-asserted-by":"crossref","unstructured":"Lu S, Xu W, Telaranta-Keerie A, Jia N HR. SAFFRON: ph3 savolitinib + osimertinib vs chemotherapy in EGFRm NSCLC with MET overexpression\/amplification post-osimertinib.Presented at: International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer; August 6-9, 2022; Vienn.","DOI":"10.1016\/j.jtho.2022.07.821"},{"key":"10.1016\/j.lungcan.2023.02.018_b0705","unstructured":"Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (SAFFRON).ClinicalTrials.gov Identifier: NCT05261399.https:\/\/clinicaltrials.gov\/ct2\/show\/N."},{"key":"10.1016\/j.lungcan.2023.02.018_b0710","unstructured":"Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy (GEOMETRY-E).ClinicalTrials.gov Identifier: NCT04816214.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT048."},{"issue":"30","key":"10.1016\/j.lungcan.2023.02.018_b0715","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR Exon 20 Insertion-Mutated Non\u2013Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study","volume":"39","author":"Park","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.02.018_b0720","article-title":"Amivantamab and lazertinib in patients with EGFR-mutant non\u2013small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2","volume":"40(16_suppl):9006\u20139006","author":"Shu","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.02.018_b0725","doi-asserted-by":"crossref","first-page":"S1560","DOI":"10.1016\/j.annonc.2022.10.424","article-title":"387P - Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study","volume":"33","author":"Horinouchi","year":"2022","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2023.02.018_b0730","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.02.018_b0735","unstructured":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial).ClinicalTrials.gov Identifier: NCT02465060.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02465060."},{"key":"10.1016\/j.lungcan.2023.02.018_b0740","unstructured":"CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation (CABinMET). ClinicalTrials.gov Identifier: NCT03911193.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03911193."},{"key":"10.1016\/j.lungcan.2023.02.018_b0745","unstructured":"A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor.ClinicalTrials.gov Identifier: NCT02750215.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02750215."},{"key":"10.1016\/j.lungcan.2023.02.018_b0750","unstructured":"Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC (Geometry-N).ClinicalTrials.gov Identifier: NCT04926831.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04926831."},{"key":"10.1016\/j.lungcan.2023.02.018_b0755","unstructured":"A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2).ClinicalTrials.gov Identifier: NCT03940703.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03940703."},{"key":"10.1016\/j.lungcan.2023.02.018_b0760","unstructured":"CNS Dose Escalation\/Expansion of Tepotinib in MET-driven NSCLC.ClinicalTrials.gov Identifier: NCT04739358.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04739358."},{"key":"10.1016\/j.lungcan.2023.02.018_b0765","unstructured":"SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients (SAFIR02_Lung).ClinicalTrials.gov Identifier: NCT02117167.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02117167."},{"key":"10.1016\/j.lungcan.2023.02.018_b0770","unstructured":"Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients.ClinicalTrials.gov Identifier: NCT04923945.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04923945."},{"key":"10.1016\/j.lungcan.2023.02.018_b0775","unstructured":"Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD).ClinicalTrials.gov Identifier: NCT03944772.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03944772."},{"issue":"1","key":"10.1016\/j.lungcan.2023.02.018_b0780","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cllc.2016.09.013","article-title":"Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non\u2013Small-Cell Lung Cancer","volume":"18","author":"Wakelee","year":"2017","journal-title":"Clin. Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2023.02.018_b0785","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cllc.2016.05.011","article-title":"Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non\u2013Small-Cell Lung Cancer","volume":"18","author":"Hirsch","year":"2017","journal-title":"Clin. Lung Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2023.02.018_b0790","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.cllc.2022.03.003","article-title":"A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib","volume":"23","author":"Camidge","year":"2022","journal-title":"Clin. Lung Cancer"},{"issue":"15","key":"10.1016\/j.lungcan.2023.02.018_b0795","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1002\/cncr.30717","article-title":"Phase 1\/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer","volume":"123","author":"Tarhini","year":"2017","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2023.02.018_b0800","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.cllc.2020.09.013","article-title":"A Phase II Study of Telisotuzumab Vedotin in Patients With c\u2013MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)","volume":"22","author":"Waqar","year":"2021","journal-title":"Clin. Lung Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022300079X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022300079X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:08:23Z","timestamp":1759237703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950022300079X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":160,"alternative-id":["S016950022300079X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.02.018","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MET alterations in advanced non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}